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Abstract: The early and late development of new anticancer drugs, small molecules or peptides can
be slowed down by some issues such as poor selectivity for the target or poor ADME properties.
Computer-aided drug design (CADD) and target drug delivery (TDD) techniques, although apparently
far from each other, are two research fields that can give a significant contribution to overcome these
problems. Their combination may provide mechanistic understanding resulting in a synergy that
makes possible the rational design of novel anticancer based therapies. Herein, we aim to discuss
selected applications, some also from our research experience, in the fields of anticancer small organic
drugs and peptides.
Keywords: drug delivery; computational chemistry; anticancer drug design
1. Introduction
Despite huge advances in the development of novel therapeutic approaches, cancer is one of
the leading causes of death worldwide; every year millions of people are diagnosed with oncological
pathologies [1] and more than half of them will die from it [2].
Small organic drugs are still the primary source of anticancer therapies counting the approval of
six new chemical entities by the food and drug administration in 2019 [3].
At the same time, while the role of peptides in the development of innovative therapies and new
diagnostic tools for oncological diseases is still marginal, it is important to note that in 2018 about
35 peptides were in different stages of clinical testing and four molecules have been approved for
the clinical use from 2000 to 2016 [4].
Synthesis and the subsequent biological tests are the heart of the anticancer drug development
process, however two other research fields, apparently far from each other, such as computational
chemistry and drug delivery, can significantly contribute to the success of new therapeutic strategies.
Computational methods, for example consolidated simulation techniques, such as molecular dynamics
(MD), docking, free energy calculations, chemoinformatic and machine learning algorithms are mainly
used to: i) design new chemical entities able to bind to a given target and ii) to improve the selectivity of
known hit or lead compounds [5–13]. Combinations of the same computational approaches can be also
employed to improve the ability of the molecules to penetrate the cells or to resist to metabolism [14–19].
Concerning targeted drug delivery (TDD), it represents a promising approach to improve treatment
outcomes through the delivery of the administered drugs to the target tissues, while eliminating or
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minimizing its accumulation at any non-target sites. Nevertheless, achieving therapeutically relevant
drug concentrations in the tumor mass, especially in the case of solid tumors, for a time sufficient to
allow the therapeutic activity of the drug, is challenging. Furthermore, high dose therapy required to
maintain the remission causes systemic side effects, forcing the discontinuation of therapy in many
patients. Thus, targeting drugs with designed drug delivery systems offers the option to enhance
the therapeutic efficacy and to reduce systemic toxicity of anti-cancer agents.
The combination of the two different research fields in this work, can probably surprise the reader,
however, we do hope that this can inspire the design of innovative scientific projects focused on drug
development and to the design of innovative therapies.
In the following, we will present and discuss some selected examples, including some from our
research experience: (1) to make more evident the real impact of computational chemistry and drug
delivery techniques in the anticancer therapies′ development and (2) to explain how these two
disciplines can directly interact.
Overall, we wish that this review could help scientists from other research fields e.g., medicinal
chemists or pharmacologists to interact with experts in computational chemistry or drug delivery to
significantly contribute to the design and development of innovative therapeutic approaches.
2. Computational Design of Anticancer Small Organic Molecules
Historically, the computational design of small organic molecules with pharmacological activity was
carried out by two different approaches the ligand-based drug design (LBDD) and the structure-based
drug design (SBDD). While LBDD is usually pursued when a significant number of molecules able to
bind a given target is known [20], SBDD approach requires the knowledge of the three dimensional
structure of the target. In the majority of the cases, the target structure is obtained by experimental
techniques such as x-ray, NMR or Cryo-EM [21], however, the homology modeling technique can be
used when the target structure is missing, but structures with sufficient level of homology (>25%–30%)
are available [22].
To note, LBDD and SBDD are not rigidly separated and their integration contributed to the success
of some studies where large libraries of compounds were screened [23].
The computational drug design process frequently requires the use of multiple techniques which
accurate description is beyond the scope of this review. Therefore, we choose to suggest some good
reviews and perspective to highlight the technical issues of the different techniques and to focus
the attention on the general computational drug design process and on some selected applications.
Concerning the SBDD the applied computational techniques can be classified into three categories
docking, MD simulations and free energy calculations.
Molecular docking algorithms are designed to predict the pose (i.e., the reciprocal orientation)
and the affinity of a molecule towards a target of interest. Over the years, the possibility to include
computationally more expensive approach and the improvement of the scoring function led to generally
good performances in the prediction of the complex structure. However, in many cases, the prediction
of the affinity for the target is still challenging and inaccurate. Multiple factors influence the quality
of the structural predictions made by a docking software. Interestingly, the problematic inclusion of
the reciprocal ligand-target adaptation during the binding process (‘induced-fit’ effect) and the possible
role of structural water molecules in the formation of the complex seem to be more important than
others [24].
Regarding the induced-fit effect, the first proposed technical solutions were based on the addition,
in the docking protocol, of some steps devoted to the sampling of the possible conformation of selected
side chains [25]. However, this type of approach does not allow to take into account larger structural
rearrangements that involves the backbone structure, and thus, they cannot be suitable to study systems
where the ligand binding induce large structural rearrangements.
Considering this limitation and taking advantage of the recent advancement in computer hardware
and of the availability of new codes able to exploit the computer power offered by the graphic processor
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unit (GPUs), this problem is increasingly addressed by using a combination of docking and MD
simulations [26] or with enhanced sampling simulations techniques such as Umbrella Sampling [27],
steered MD [28], metadynamics [29] and supervised MD [30]. Running MD simulations for a sufficiently
long time or coupling MD simulations with enhanced sampling techniques, enable the observation of
rare events as ligand binding/unbinding, loop or channel opening/closure, protein folding.
In addition, the presence of crucial water molecules have been investigated by specialized
algorithms as those implemented in the GOLD docking software [31] that permit to turn on/off
the presence of a single water molecule inside the catalytic site or by the use of MD simulations [24,32–34].
Concerning the scoring of the ligand-protein affinity, many efforts have been devoted to improve
the performance of the scoring functions, e.g., taking into account the ligand-target polarization
effect by quantum mechanics/molecular mechanics QM/MM calculations [35,36], or using artificial
intelligence to improve their general predictivity [10].
A significant contribution to the affinity predictions comes from the endpoint free energy methods
such as MM-GB(PB)SA and Linear Interaction Energy (LIE). In both approaches, multiple conformations
of the final state of systems are sampled by MD simulations, and the binding free energy is estimated
by approximated expressions [12,37].
In particular, for MM-GB(PB)SA the difference in free energy (∆G) is expressed as:
∆G = Gcomplex − (Greceptor − Gligand) (1)
∆G = ∆H − T∆S (2)
The enthalpic contribution ∆H can be decomposed in two contributions ∆GMM and ∆Gsolv., ∆GMM
can be additionally decomposed in three contributions ∆GvdW, ∆Gelc and ∆Gint that express the change
in the van der Waals, electrostatic and e conformational energy, calculated at a molecular mechanics
level. ∆Gsolv can be expressed as the sum of ∆Gsolv-pol„ which is the electrostatic contribution to
the solvation energy, calculated applying the Poisson–Boltzmann or the Generalized Born equations,
and ∆Gsolv–nopol that it is estimated considering the variation the surface accessible area (SASA).
Since it is difficult to accurately estimate ∆S, it is frequently neglected when similar ligands are
compared [38], however, it can be estimated by normal-mode analysis when the determination of
a more rigorous ∆G is required.
Differently, in the LIE approach ∆G is expressed by Equation (3):
∆G = α〈VvdwLprot −VvdwLsolv〉+ 〈βVelecLprot −VelecLsolv〉 (3)
where VvdwLprot and V
vdw
Lsolv are the average van der Walls and the electrostatic interaction energy of
the ligand inside the protein or in the solvent and 〈 〉 indicates that the quantity is calculated over
a conformational ensemble (ensemble average). α, β represent empirical coefficients that depend on
the nature of the system [39–41].
However, from the theoretical point of view, accurate results can be obtained only by the application
of rigorous physical techniques such as Thermodynamic Integration (TI) or Free Energy Perturbation
(FEP). For different reasons, such as the high computational costs and difficulties in obtaining convergent
results for structurally unrelated compounds, these methods are still frequently applied only to the subtle
optimization of compounds and not to the screening of small or large libraries. However, as recently
pointed out by Williams-Noonan et al. [13], they are close to becoming a mainstream tool for medicinal
chemists in the next few years.
2.1. Selected Examples of Anticancer Small Molecules Design
Scientific literature reports hundreds of studies where computational methods support
the development of anticancer drugs [42,43]. Therefore, herein, we discuss only a few selected
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examples, one also from our research experience that can give the idea of how computational methods
can be used in anticancer drug design.
One interesting example concerns the design of new human aromatase (HA) inhibitors. HA is
a P450 cytochrome (CYP450) in charge for the conversion of androgens to estrogens and one of the main
targets of the therapies against ER-positive breast cancer. Being that HA is a CYP450, it is characterized
by a hidden catalytic site. Therefore in 2012, Sgrignani and Magistrato started to investigate the channels
traveled by the substrate to enter/exit to/from the active site by computational methods [27,44,45].
In particular, after the generation of the first atomistic model of HA placed on a mimic of the endoplasmic
reticulum membrane formed by 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) molecules,
they used random expulsion MD simulations (RAMD) to map an ensemble of putative channels. In fact,
during RAMD simulations, a force of random direction and known intensity is imposed to the ligand
and if this is able to move above a given distance threshold, in a given time interval, the direction is
conserved, otherwise it is changed. As result of this procedure multiple unbinding events, in this case
one hundred, can be sampled in a reduced simulation time. Finally, the unbinding trajectories have
been clustered to identify some representative of really different enter/exit pathways and the steered
MD (SMD) technique has been used to determine the most favorable. Differently than in RAMD,
during SMD simulations, a force of know direction is imposed on the ligand in order to induce its
distancing from the binding site at a constant velocity. This procedure allowed to calculate the work
necessary to pull-out the ligand that has been used as measure of the accessibility of the channel.
This work indicated that (1) the membranes’ environment significantly influence the results and it has
to be considered in the modeling of HA and (2) two favorable access/release channels can be identified.
In 2017, thanks to the rapid availability of higher computational resources, Magistrato et al. [27]
reconsidered their previous results and used umbrella sampling (US) simulations to obtain the free
energy profile along the previously identified channels. This study indicated one of the channels
as the most probable and contributed to the identification of structural rearrangement necessary for
the passage of substrates and inhibitors.
Historically, HA inhibitors have been always designed as competitive ligands for the catalytic site
and other never explored routes [46,47]. However, in 2014, inspired by biochemical studies carried out
by the group of D. Flockhart [48–50] reporting the non-competitive inhibition of HA by some tamoxifen
metabolites, Sgrignani et al. [51] also performed computational studies aimed to locate an allosteric
site on the HA surface and to understand the mechanism of the non-competitive inhibition. The study
started from the identification of some putative allosteric sites present on the HA surface made by
the Sitemap software [52,53], then docking, MD and MM-GBSA simulations have been used to identify
which sites were suitable to bind the tamoxifen metabolites with a predicted affinity consistent with
the experimental data and to propose some mechanism of allosteric inhibition.
The information obtained from these studies, in particular those concerning the localization of
the channels, have been later used to identify new allosteric or dual-mode (allosteric and orthosteric)
HA inhibitors [54,55]. Specifically, they used docking based virtual screening, molecular dynamics
and free energy calculations to identify some hits that represent the starting point for subsequent
optimization studies. To note, the ability of the identified compounds to inhibit HA was proved by
biochemical and cellular experiments [54,55].
Another interesting example about computer-aided anticancer design is represented by the study
by Cherkasov and coworkers concerning the identification by virtual screening of one molecule able
to inhibit the transcriptional activity of the ERG protein, a transcription factor identified to be highly
expressed by prostate cancer cells. In this case, starting from the structure of the ETS-ERG, an ERG
domain that has been proved to interact with DNA [56] directly, they localized a putative drug binding
site using the Site Finder algorithm implemented in the Molecular Operating Environment (MOE).
Therefore, they processed a library of 20 million compounds obtained from ZINC (a large
database of commercially available molecules) to select a sub-library of 3 million compounds with
the following properties: molecular weight between 250 and 400 Da, logP ≤ 5, hydrogen-bond donors
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≤5, hydrogen-bond acceptors ≤10, number of rotatable bonds ≤10 and number of rings ≤4. The ability
of these compounds to bind ERG was evaluated by virtual screening using the Glide algorithm [57]
and, only for top 30,000 molecules from this first calculations also by eHiTs docking program [58].
Finally, the poses of the best 3000 compounds (ranked by a consensus score) were visually analyzed
and 48 molecules were selected for biological tests.
The obtained results indicated a molecule (VPC-18005) as the more promising compound.
The interaction of this molecule with the target was finally proved by NMR spectroscopy and its effects
on the prostate cancer cell investigated by molecular biology.
2.2. Computational Design of Anticancer Peptides
Peptides have been considered, for a long time, a niche area with reduced perspectives of
development. This was mainly due to some intrinsic characteristic of this class of molecules such
as inability to permeate cellular membranes, biological instability, low oral bioavailability and the capital
roles played by peptides in the endocrine signaling [59]. However, it is widely recognized that they
also offer multiple advantages, being well suitable to replace endogenous agonists or to target
protein-protein interactions. Moreover, multiple strategies, such as the inclusion of unnatural amino
acids, backbone modifications and novel formulations, allowed to overcome the previously discussed
limitations giving a significant impulse to the peptide drug development.
Computational peptide design (CPD) is preferentially performed using a structure-based approach.
The structures of protein-protein complexes are the major source of peptide sequences to be used in
therapeutic peptide design, however, this type of information is not always available and then a great
contribution can come from computational chemistry. Considering to have one or more bioactive
peptides coming from random libraries, obtained from phage display or isolated from natural sources,
for which not even a crude structural model is available, the first step to undertake a computational
study aimed to improve the peptide affinity and selectivity for a given target is the building of
a reliable model of the peptide-target complex. As a result of the larger conformational space explored
by peptides with respect to small molecules, it is common opinion that the consolidated docking
algorithms, widely used in drug design, are not suitable for this type of investigation, therefore
specialized docking algorithms integrated, using experimental restrains, when it is possible, can help
to identify the correct structure [30,60].
Once a structural model of the complex is available both MD simulations and/or free energy
calculations demonstrated that they can significantly contribute to design peptide modifications that
results in an improved affinity and selectivity [61,62]. In particular, starting from the assumption that
a significant increment of the affinity for the target would result also in an augmented selectivity, multiple
methodologies with different degree of complexity such as thermodynamic integration or free energy
perturbation [63,64] metadynamics [65,66], MM-GB(PB)SA [5,67,68] aimed to estimate the binding
free energy (∆G) computationally, have been applied to evaluate which peptide modifications could
result in a more favorable (more negative) binding energy. Additionally, in this case, literature reports
some interesting examples about the use of computer simulations in the design of anticancer peptides,
therefore we selected some of them to give to the reader a flavor of the impact that computer simulation
had on this research field in the last ten years. Nevertheless, computer simulations of biological systems
root in the 1970s [69], only the great technological progress such as computing by graphic processor
units (GPUs) or the development of highly parallel codes [70,71] enabled computer simulations to
really impact the peptide therapeutic development and to enrich the scientific literature in the last
ten years.
2.3. Selected Examples of Anticancer Peptide Design
The work of Spodzieja et al. [72] represents an interesting example about the use of the structure
of protein-protein complexes in computational design of anticancer peptides. In fact, their study
was focused on the design of a peptide inhibitor of the herpes virus entry mediator (HVEM) protein,
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which is frequently expressed in melanoma cells and indicated as a possible target for anticancer
immunotherapy. The visual observation of the structure of the complex’s structure of the complex
between HVEM and the B and T lymphocyte attenuator (BTLA) protein suggested that a 17 residue
aminoacidic extracted from HVEM (positions 23–39) could antagonize the formation of the HVEM-BTLA
complex. This hypothesis was preliminarily verified by 10 ns long MD simulations that confirmed
the ability of the peptide to bind BTLA. Experimental tests indicated that the peptide can really hinder
the protein-protein interactions, however they also pointed out that this effect is mainly linked to
the presence of a free cysteine in the peptide suggesting that the observed effect could be due to
the formation of a covalent BTLA-peptide complex and not to the formation of a complex with the same
structure observed in the X-ray experiments.
Another interesting example about the use of computational chemistry techniques to increase
the affinity of peptides to a given target concerned the optimization of a 12-residue peptide modulator
(L-peptide, sequence: RLLDTNRPLLPY). This peptide was firstly identified by phage display
experiments [73], carried out to identify peptides able to specifically bind Nasopharyngeal carcinoma
(NPC) cells. Nevertheless, even if this peptide was designed to bind specific cells, showing a clear
biological effect, its molecular target was unknown. Therefore, some years after its first publication,
Yu and coworkers applied the PepBind program [74] to identify the molecular target of the peptide,
concluding that the human glucose-regulated protein 78 (GRP78) protein could be the molecular
counterpart of the L-peptide. GRP78 is a protein located in the endoplasmic reticulum (ER), where
it is involved in the promotion of protein folding and in the activation of unfolded protein response
pathway (UPR). Due to high ER stress level, this protein is highly expressed on the surface of many
cancer cell lines and, therefore, it is a promising target for the development of innovative anticancer
therapies. At the beginning of the study, the structure of GRP78 was still unknown; therefore
computational studies, aimed to optimize the peptide, started with the generation of the structural
model of the target by homology modeling considering different proteins such as DnaK and Hsc70
as the template [75]. Subsequently, the Dock [76] program and the Hotlig suite [77] were, respectively,
used to produce a structural model of the protein-peptide complex and to analyze the interactions
between the two molecules. The structural model of the protein-peptide complex was finally used to
design a library of 400 peptides to be screened in-silico for their ability to bind GRP78. The performed
calculations identified a group of 17 peptides that could bind the target better than the original
L-peptide. These molecules were synthetized and their ability to bind GRP78 verified by surface
plasmon resonance (SPR) experiments. Four peptides, approximately the 25% of the tested molecules,
displayed a better affinity for the target.
In recent years, some of the authors of this review applied the combination of the structural
modeling and MM-GBSA calculations to the optimization of peptides able to inhibit the Proprotein
convertase subtilisin/kexin type 9 (PCSK9). The evidence about the relevance of PCSK9 inhibition to
develop anticancer therapies is still not clear, while it is well known that this protein is one of the main
targets for the therapies against hypercholesterolemia [78]. However, the strategy pursued to optimize
one peptide (T9) selected by the screening of peptide molecules derived from the hydrolysis of lupin
protein was successful and therefore could represent a suitable strategy also to optimize the affinity
of anticancer peptides (Figure 1). PCSK9 regulates the low-density lipoprotein receptor (LDLR)
degradation by direct interaction with this protein. In particular, it has been demonstrated that gain of
functions (GOF) mutations able to increase the PCSK9-LDLR affinity result in an augmented LDLR
degradation that has as final effect a significant increment of the circulating cholesterol concentration.
The T9 peptide (GQEQSHQDEGVIVR) was firstly identified, together with other peptides, in
a study aimed to investigate the ability of a group of molecules obtained from the hydrolysis of lupin
protein to suppress the PCSK9-LDLR interaction [5]. Further studies pointed out that, differently from
the other peptides reported in the original study, T9 is able to suppress also the binding between
the mutated PCSK9D374Y and the LDLR even with an EC50 value of 285.6 ± 2.46 µM [79].
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In all these studies computational techniques have been used to obtain a structural model of
the PCSK9-LDLR complex; moreover, in the case of T9, a specific computational protocol was applied
also to improve it affinity for PCSK9D374Y [62].
In particular, computational alanine scanning calculations, based on the MM-GBSA
technique [80,81] were firstly used to identify the “non-hot-spot” residues, e.g., the residues not
essential for the binding. Interestingly, these calculations led to the discovery that the simple
substitution of the aspartate residue in position 8 of T9 with an alanine could result in an improved
affinity. This prediction was confirmed by in-vitro experiments.
Figure 1. Schematic representation of a computational pipeline for peptide optimization.
MM-GBSA calculations identified also other additional non-hot-spot residues, therefore starting
from the T9D8A structure 10.000 new peptides were generated by changing the residues at the identified
positions with all the other natural amino acids but accepting only two simultaneous mutations.
The affinity for the target of these new residues was firstly evaluated by the scoring function
implemented in Prime (Prime, Schrödinger, LLC, New York, NY, USA), therefore the structures of
the complexes between PCSK9D374Y and the top-ranked peptides were simulated by MD for 100 ns
and the peptide-protein affinity estimated by MM-GBSA. However, the results of these calculations
indicated that none of the hypothesized mutations could actually improve the affinity for the T9
binding when compared to other positions more crucial for the T9 binding and not initially classified
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as non-hot-spot residues, when investigated using the same computational protocol. Finally, a new T9
derivative (T9D8A_1) was identified and the in-vitro test confirmed that the EC50 able to block the T9 -
PCSK9D374Y is reduced by more than the 50% compared to the original T9 peptide.
3. Advanced Drug Delivery Approaches
In the following chapter, we will discuss a range of drug delivery strategies, and focus on some
from our research experience, given their potential for targeted therapies.
3.1. Oncolytic Viruses in Drug Delivery
Cancer continues to be one of the most difficult global healthcare problems. Although there is
a large group of drugs that can be used in cancer treatment, the problem is the selective killing of
cancer cells while reducing collateral toxicity to healthy cells. In addition to incrementing the affinity
to the macromolecular target, drug selectivity can also be incremented by innovative drug delivery
strategies (Figure 2).
Figure 2. Innovative drug delivery strategies.
Concerning the oncological therapies, one of the most important sources of resistance to
chemotherapy, apart the ability to develop cellular mechanism of drug resistance, is the tendency of
some tumors to proliferate in the so-called sanctuary sites (i.e., central nervous system, peritoneum
and testis) [82], anatomical spaces where the drugs cannot reach the therapeutic levels. Moreover,
an indiscriminate distribution of chemotherapeutic drugs also to healthy tissues is cause of side
effects. To overcome these issues, various drug delivery systems have been extensively investigated
demonstrating that they can effectively improve the selectivity and safety of the drugs [83]. However,
the precise delivery of active drugs to cancer tissues is still challenging [84] and this issue still represents
an unmet medical need.
In the following, we will discuss some very interesting drug delivery strategies such as oncolytic
viruses (OVs), liposomes, antibody drug conjugate and extracellular vesicles.
OVs are an emerging class of anticancer bio-therapeutics able to selectively auto-replicate in cancer
cells without causing damage to normal cells [85,86]. They can be either naturally tumor-selective
viruses, like reovirus and Seneca Valley virus, or genetically modified so that their replication is
dependent on cancer-related pathways, such as adeno, vaccinia, herpes simplex, measles and Newcastle
disease viruses. Furthermore, OVs have shown a potential for the treatment of cancer along with
the safety profile as verified in many preclinical studies and clinical trials [87–89].
Importantly, the US Food and Drug Administration (FDA) and European Medicines Agency (EMA)
in 2015 have approved T-VEC (Imlygic), an oncolytic herpes virus lacking ribonucleotide reductase
and also expressing granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of
locally advanced or non-resectable melanoma, opening the way for new therapeutic protocols [90].
However, clinical data highlight that the efficacy of OVs as single agent remains limited, suggesting
that patients may benefit from combination therapies. In fact, OVs exhibit different mechanisms
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of action from conventional anticancer approaches giving a possibility for additive or synergistic
interactions in cancer therapy [91–93]. Nevertheless, there has been huge progress with anti-cancer
therapies with encouraging clinical results, there are still many limitations that should be tackled to
improve the efficacy of oncolytic virotherapy [94–96] including: viral tropism, delivery platforms,
viral distribution and oncolysis by the OVs. Although the greatest effect of OVs consists of their
selective infection and replication in cancer cells, the ability to deliver OV particles efficiently to
tumors still constitutes a hurdle. In fact, in order to establish a niche within the tumor after a systemic
injection, OVs have to bypass the liver that could sequester a percentage of the administered dose.
Therefore, administering the virus directly within the tumor overcomes this limitation, reducing
the possibility of treating solid tumors where the logistics of intralesional administration may prohibit
its use. In addition, as most OVs are ubiquitously present in nature and humans could have been
infected or vaccinated against some, patients might have neutralizing antibodies that can bind the virus,
reducing the viral spread and limiting the targeted delivery [97]. In addition to that, the OV-efficacy
in monotherapy is limited, therefore, in order to enhance their efficacy, novel approaches able to
combine OVs with anticancer agents are remarkably increasing [98]. In addition to the possibility of
a combination regime in which OVs are administered with free drugs, another approach has been
proposed to absorb anticancer drugs, for example, L-carnosine, on the adenoviral capsid, based on
electrostatic interaction and exploited this strategy for cancer drug delivery [99,100]. The studies
were designed to evaluate the oncolytic potency of OVs and its anti-cancer efficacy in combination
with L-carnosine in human colorectal and lung cancer animal models revealing that the intratumoral
administration of the complex (OVs complexed with L-carnosine) resulted in significant synergistic
tumor suppression [100].
Considering that OVs have a unique ability to selectively replicate in cancer cells, a clinically
relevant strategy, able to accelerate their cytotoxic properties and improve oncolysis, is their combination
with chemotherapeutics [101]. Therefore, since chemotherapy can enhance the replication of oncolytic
viruses and weaken the immunosuppressive tumor microenvironment [102], a clinically highly relevant
strategy is the use of OVs with chemotherapeutic agents which can enhance anticancer killing efficacy
and induce anticancer immunity [91]. For example, combining the oncolytic virus ONCOS-102 with
chemotherapy [91,93,103] can overcome the immune suppressive tumor microenvironment [104] due
to the immunogenic tumor cell death induction properties [105–108] and subsequently mediation
of anti-cancer immune responses [105,109,110]. In fact, emerging findings suggest that the clinical
outcome of conventional chemotherapy is not only attributed to tumor cell toxicity but also results
from the induction of anti-cancer immune responses. Antitumor immune response can be primed by
immunogenic cell death (ICD), which is characterized by cell-surface translocation of calreticulin (CRT),
extracellular release of ATP, high mobility group box 1 (HMGB1) and stimulation of type I interferon
(IFN) responses. The conventional chemotherapeutics can work as ICD inducers, which are capable
of modulating tumor-infiltrating lymphocytes (TILs) and reactivating antitumor immunity within
an immunosuppressive microenvironment. Such immunological effects of conventional chemotherapy
are critical for the better prognosis of cancer patients [111].
OVs can serve as an immunesensitizer in combination therapies with checkpoint inhibitors [112].
The discovery of immune checkpoint inhibitors (ICIs) such as anti- CTLA-4, PD-1 and PD-L1
is a revolutionary milestone in the field of immuno-oncology, holding promising therapeutic
outcomes [113]. Tumor cells evade immunosurveillance and progress through different mechanisms,
including the activation of immune checkpoint pathways that suppress antitumor immune responses.
Checkpoint inhibitors have revolutionized the treatment of advanced melanoma by releasing
suppression of T-cell immunity in the tumor milieu, by inducing durable clinical antitumor immune
response and supporting long-term survival in patients [114]. Nevertheless, despite the success of ICI
therapies, only a fraction of patients benefit from it with the best response rates that do not exceed
35% to 40% [115,116]. However ICIs have the capacity to synergize with other approaches to activate
anti-cancer immune responses [117]. For example, a study in humanized mice engrafted model
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with A2058 melanoma cells showed significant tumor volume reduction after ONCOS-102 treatment.
Importantly, the combination of pembrolizumab with ONCOS-102 reduced tumor volume to an even
greater extent, while pembrolizumab alone did not show any therapeutic benefit by itself supporting
the scientific rationale for the combination therapies [92].
Future studies on oncolytic virotherapy should focus on innovative strategies and overcome
current challenges and limitations by using recombinant OVs to create solid foundations for future
clinical success.
3.2. Liposomes
Liposomes are phospholipid-based vesicles, with a diameter range of 50–200 nm for parenteral
administrations, in which the circular bilayer creates an aqueous core. This structure offers the possibility
to entrap both hydrophilic molecules, hosted in the aqueous space, and hydrophobic molecules,
inserted within the lipid bilayer. They possess unique properties owing to the amphiphilic character of
the lipids and several advantages such as biodegradability and biocompatibility which makes them
suitable delivery systems [118], furthermore, their composition, surface charge and functionalization,
size and other physicochemical features can be controlled in order to modulate biological processes
such as drug release, circulation time and biodistribution [119,120]. Liposomes emerged as sustained
drug release systems able to increase the delivery of therapeutic agents to the tumor site and reduce
the off-target toxicity of the anticancer drug. Liposomes have been firstly investigated as drug carriers
in 1973 [121], leading to considerable improvements in pharmacokinetics of the encapsulated drug,
slowing the rate of drug clearance and displaying a minor tendency to localize in healthy tissues when
compared to the free drug.
Liposomal drug delivery systems enable the delivery of higher drug concentrations allowing
targeting specific cells or organs [122,123], thus minimizing the distribution of the drug to non-targeted
tissues. Nevertheless, the uptake by the mononuclear phagocyte system, in liver and spleen, represents
the principal mechanism of liposomal clearance from the bloodstream, thus preventing the full
exploitation of the advantages of this drug delivery system. To circumvent this issue, the anchoring of
hydrophilic polymers has been proposed, such as PEG able, to the surface of the liposomes and create
a barrier against the adherence of opsonins that can enhance phagocytosis. Stealth® liposomes, with
PEG on the outer membrane, display steric stabilization and low opsonization with reduced uptake
and clearance by the mononuclear phagocyte system. These liposomes have an extended circulation
time and represent an efficient carrier able to reduce the mononuclear phagocyte system uptake while
supporting the delivery of therapeutic drugs to cells or tissues [120,124].
Currently, several liposomal formulations have been used in clinic, including the first
FDA-approved Doxil®, a PEGylated doxorubicin liposome formulation for the treatment of solid tumors,
and Marqibo®, the latest FDA approved liposome formulation which is a sphingosomal/cholesterol
encapsulation of vincristine sulphate for the treatment of Philadelphia chromosome-negative acute
lymphoblastic leukemia [125].
In a recent work aimed to treat glioblastoma, PEGylated liposomes have been employed for
the delivery of resveratrol in order to improve solubility and stability [126]. Using transferrin for
the active targeting, transferrin receptors are upregulated in glioblastoma. In addition, rhodamine-labeled
transferrin-modified liposomes demonstrated higher association with cancer cells compared to
human astrocytes, with significant internalization in cancer cells compared to non-targeted liposomes.
Interestingly, resveratrol-loaded transferrin-modified PEGylated liposomes inhibited tumor growth
and improved survival in mice suggesting their application could be a valuable strategy for the treatment
of glioblastoma.
So far, clinically approved liposome drug formulations do not include specific active-targeting
strategies (Doxil®/CaelyxTM, DaunoXome®, Myocet®, Marqibo®, Onivyde®, VyxeosTM); however,
a doxorubicin-loaded immunoliposome targeted with Cetuximab (mAb epidermal growth factor
receptor (EGFR) inhibitor) Fab fragments is in Phase II clinical trials for the treatment of advanced
Molecules 2020, 25, 1756 11 of 22
triple-negative EGFR-positive breast cancer (Clinical trial NCT02833766). Future directions may
include some strategies for the co-administration of two targeted formulations or the combination of
two drugs within a single targeted carrier.
3.3. Extracellular Vesicles and Cancer Drug Delivery
In the last decades, extracellular vesicles (EVs) have been found to exert different biological functions
in both physiological and pathological conditions explaining the rapid growth of interest in this research
field. EVs are nano- to micron-sized lipid membrane-bound vesicles secreted into the extracellular
environment transporting proteins, lipids and nucleic acids from cell to cell [127]. They are naturally
occurring cargo delivery agents with the potential to be used as vehicles for drug delivery [128,129].
Due to their natural origin, their efficient internalization by recipient cells and their natural ability to target
specific cells or organs [130,131], they are considered as ideal carriers for therapeutic agents. Hong et al.
developed engineered enzymatic EVs with the native glycosylphosphatidylinositoll (GPI)-anchored
form of hyaluronidase (Exo-PH20) to overcome the immunosuppressive tumor microenvironment [132]
showing that the EV-mediated codelivery of PH20 hyaluronidase and a doxorubicin efficiently inhibits
tumor growth.
Currently, different strategies can be used to load the therapeutic cargo within the EVs. The cargo
can be loaded into EV producing cells or post-EV formation by electroporation, passive incubation
or destabilizing the EV membrane [131,133]. A variety of therapeutic agents have been loaded into
EVs in order to increase their accumulation inside target cells [134–136]. For example, curcumin
and doxorubicin exhibited a high drug loading efficiency and an increased cytotoxic effect when loaded
inside EVs compared with the free drugs [137,138]. Due to their natural origin, EVs have recently
had considerable attention as non-immunogenic drug delivery vehicles [130,139], and the systemic
(i.v. or i.p.) route of administration was chosen in different in vivo preclinical studies [140–142]. In fact,
recent studies report that the systemic delivery of cancer derived EV-formulations containing OVs
were effective in reducing lung tumor growth in nude mice and were able to protect the virus from
immune disruption through the encapsulation into EVs, suggesting that the procedure could protect
the OVs against their disruption by the host immune system, while efficiently targeting the therapeutic
particles into the neoplastic tissue [135].
The organotropism of EVs, the absence of immunogenicity, natural composition and ability to be
loaded with small molecules and biologics are of interest for the development of nano-based drug
delivery systems (DDSs) and theranostics applications [125,143,144]. Nevertheless, although highly
attractive, the use of EVs in clinical applications remains limited because the molecular basis of their
tropism and targeted delivery to cancer cells has not been thoroughly elucidated. Several studies
reported that the tumor tropism of EVs might be related to the adhesion-associated molecules on
their surface, such as integrins, tetraspanins and other glycoproteins [145]. However, there is no clear
consensus whether the tumor tissue originating the EVs dictates their tropism [146]. Furthermore,
bioluminescence and fluorescence imaging technologies indicate a selective delivery of EVs to the tumor
tissue allowing to insulate the delivered agents, thus potentially preventing undesired off-target effects of
the transported drugs due to their systemic delivery [147]. Interestingly, another advantage of using EVs
is their heterologous and cross-species cancer specific homing capabilities that could open new avenues
for the selective delivery of diagnostic/therapeutic agents to different tumor types [127]. The possible
existence of a selective ligand-receptor mechanism responsible for the EV-tumor tropism paves the way
for future research aimed at developing biocompatible nanovesicles with a cancer-selective homing
which is instrumental for future clinical applications where the delivery of diagnostic agents may be
combined with the loading of drugs or radiotherapeutic isotopes for curing tumor micrometastasis
and residual neoplastic cells eventually remaining in the normal tissue after conventional cancer
treatments [148].
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3.4. Antibody-Drug Conjugates
Antibody drug conjugates (ADCs) are a class of anticancer therapeutics based on the direct
conjugation of drug molecules to proteins in order to target the delivery of drugs to precise site
of action [149]. The first ADC’s study linked the anticancer drug methotrexate to a polyclonal
leukemia cell-targeting antibody in an attempt to target diseased tissue while leaving healthy tissue
unharmed [150].
The first clinical trial with an ADC, conducted in 1983 by Ford and colleagues, employed an anti-
carcinoembryonic antigen-antibody conjugated to vindesine, which is a vinca alkaloid, for the treatment
of patients with advanced metastatic colorectal or ovarian carcinoma [151] revealing, by detecting
radioactivity from the 131I labeled ADC, that five of the eight treated patients showed a clear localization
of the ADC at the tumor site. An important translational aspect is related to the amount of ADC that cell
receives. Clinical observations for many ADCs, such as ado-trastuzumab emtansine and mirvetuxi-mab
soravtansine in breast and ovarian cancer patients, support the concept that the internalization by
the cell, with accumulation of the cytotoxic activity, is directly related to target antigen density.
Therefore, ADC therapy may be optimized by selecting patients whose tumors express target antigens
above a threshold level necessary for antitumor activity [152]. To date, four ADC therapeutics received
marketing approval: i) Mylotarg [153], gemtuzumab ozogamicin targeting the CD33 antigen was
approved in 2000 for treatment of acute myeloid leukemia, and later on withdrawn in 2010 by
the FDA as it failed to meet the efficacy targets; Mylotarg was re-introduced in 2017 with lower
recommended dosage and different treatment schedule (alone or in combination with chemotherapy)
for newly-diagnosed CD33-positive acute myeloid leukemia patients; ii) Adcetris – Brentuximab [154],
vedotin targeting the CD30 antigen has been approved for the treatment of relapsed or refractory
Hodgkin lymphoma and systemic anaplastic large cell lymphoma and several phase III trials are in
progress to confirm clinical benefit of Brentuximab in randomized studies in combination with approved
chemotherapeutic agents (NCT01712490, NCT01777152), as well as in combination with immune
checkpoint inhibitors (NCT02684292, NCT03138499); iii) Kadcyla [155]-Trastuzumab-emtansine
targeting the HER2/neu receptor for the treatment of HER2-positive metastatic breast cancer; iv)
Besponsa-Inotuzumab [156] ozogamicin targeting the CD22 antigen used for the treatment of relapsed
or refractory B-cell precursor acute lymphoblastic leukemia. The successful approvals of brentuximab
vedotin, ado-trastuzumab emtansine and inotuzumab ozogamicin after decades of disappointment in
developing immunoconjugates as therapeutic agents have attracted a lot of attention and more than 80
ADCs have entered clinical evaluation over the last 15 years [157].
However, the relatively benign side-effect profiles for many ADCs suggest that it could be
combined with other agents in order to improve patient outcomes. In fact, mirvetuximab soravtansine
is being evaluated in combination with carboplatin, pegylated liposomal doxorubicin, bevacizumab
or pembrolizumab, in a trial called FORWARD II (NCT02606305) [158]. Furthermore, it has been
suggested that the ADCs may be combined with immune checkpoint inhibitors such as the anti-PD1
antibodies (pembrolizumab, nivolumab) for enhanced and sustained antitumor effect [159].
Nevertheless, the large variety of ADC technologies developed over the past decade provides
different possibilities for designing an ADC specific to a given target [157]. There are new-generation
linker chemistries that result in improved antitumor activity and a wider therapeutic window in
preclinical studies when compared with the approved ADCs [160–162]. In addition to that, there are
still important parameters which need to be optimized such as the ADC stability which includes the rate
of drug loss due to linker instability and the impact of conjugation on the antibody itself that can affect
the pharmacokinetic and biodistribution. Interestingly, the instability of ADCs in the circulation may
also be overcome by alternative bioconjugation chemistries with the aim to enhance homogeneity
and to reduce the drug deconjugation rate in the circulation in order to limit off-target toxicity while
increasing the delivery of drugs to tumors.
Future developments to increase the therapeutic index of ADCs have to be made either in
the potency of the cytotoxic agent to reduce the minimum effective dose or improve the tumor
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selectivity while increasing the maximum tolerated dose. Currently, there is still a lot to learn about
the optimal application of ADCs in the treatment of different cancers, especially in establishing the role
of ADCs in combination with immune-oncology therapies. Nevertheless, the opportunity to improve
treatment outcomes for cancer patients by incorporating ADCs into cancer therapy offers exciting
possibilities for the future.
4. Computational Chemistry in the Design of DDS
For many years, delivery systems such as OVs, liposomes, antibody drug conjugate
and extracellular vesicles have been considered to have too large dimensions for investigations
using MD simulations. In fact, the simulation time, which is required to run MD simulations, directly
depends on the number of atoms, that for such complex systems can frequently be also some millions.
Therefore, for some years, computational studies have been mainly focused on some relevant
aspects for the drug delivery field such as the permeation of a drug across a membrane bilayer by using
simplified systems [18,163–165] However, recent advances, as the computing by graphic processor
units (GPU) and the availability of atomistic or coarse-grain force field, enables to investigate these
systems accurately and in a reasonable time.
The development of antibody drug conjugates appears to be the most mature field for
the application of computational methods [166] since docking, molecular dynamics and free energy
calculation can be used to both speed-up the design of specific antibodies [167] and to investigate
the interaction of the antibody with an additional carrier [168].
Concerning liposomes, Hashemzadeh et al. [169] recently reported the use of coarse-grain MD
simulation to investigate the behavior of liposomes formed by 1,2-distearoyl-sn-glycero-3-phosphocholine
(DSPC) and DPSM (Egg sphingomyelin). The results of the simulations indicated that even if DSPC
and DPSM are usually used to generate liposomes and micelles, during the simulations of the self-assembly
process, they form some nanodisc structures. This information can be useful in the future for further
development of liposomal based formulations.
Regarding OVs, the computational hardware, currently available in the majority of
the computational chemistry labs, cannot sufficiently simulate so large and complex systems, nevertheless
some researchers demonstrated that the simulation of an entire viral capsid is possible [170,171]
suggesting that, by improving the computational power, the computational design of very complex
systems, such as OVs, will be routinely accessible.
5. Conclusions
Targeted cancer therapy relies on DDS able to deliver anticancer agents safely to tumors while
minimizing systemic toxicity. This goal can be pursued by the identification of highly selecting
compounds or developing strategies that maximize drug concentration in tumor compared to
healthy tissue. The examples discussed in this review demonstrate that computational chemistry is
becoming more and more important in improving the potency and selectivity of anticancer drugs
and that advanced drug delivery techniques can significantly contribute to the development of new
therapeutic approaches.
For many years the lack of computational resources limited the interaction between the two
disciplines to which this review is dedicated, consequently computational strategies are not widely
used for the design of DDS. In particular, most of the computational studies focused on specific aspects
of the drug delivery development such as the calculation of the drug physicochemical properties or
membrane permeability processes instead of studying the entire DDS.
Nevertheless, as science is evolving, we expect that in the next few years computer aided DDS
design (CADDSD) should be increasingly combined with wet-lab techniques to facilitate the design
of new therapeutic strategies aiming to (1) predict better and better the behavior of DDS under
physiological environment, and (2) to design molecules able to drive the DDS at the right place to
maximize targeting efficiency and minimize drug dosage.
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